ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)

NO_LONGER_AVAILABLE

Conditions studied: Critical COVID-19 With Respiratory Failure

In brief

Patients with Critical COVID-19 and respiratory failure who are ineligible for enrollment in NCT04311697, who live more than 50 miles from an existing collaborating research center, or who are already hospitalized and cannot safely be transferred to a collaborating research facility may be considered for expanded access by the sponsor. Treating physicians must complete FDA Form 3396 and receive a letter of authorization from NeuroRx, along with local IRB authorization. Please refer to FDA guidance for Individual Patient Expanded Access https://www.fda.gov/media/91160/download

Key facts

Study ID
NCT04453839
Run by
APR Applied Pharma Research s.a.
Last updated by the study team
2023-02-03

Who can join

Age: 12 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.